vs
Lantheus Holdings, Inc.（LNTH）与RBC Bearings INC（RBC）财务数据对比。点击上方公司名可切换其他公司
RBC Bearings INC的季度营收约是Lantheus Holdings, Inc.的1.1倍（$461.6M vs $406.8M），RBC Bearings INC净利率更高（14.6% vs 13.3%，领先1.3%），RBC Bearings INC同比增速更快（17.0% vs 4.0%），RBC Bearings INC自由现金流更多（$99.1M vs $81.4M），过去两年RBC Bearings INC的营收复合增速更高（5.6% vs 4.9%）
Lantheus Holdings是一家全球性医疗保健企业，专注于研发、生产及商业化创新诊断显像剂与相关解决方案，产品覆盖肿瘤学、心脏病学、泌尿学等核心医疗领域，主要市场遍及北美及全球其他重点地区。
该文本实际介绍的并非RBC Bearings，而是美国多佛公司。多佛是一家工业产品综合制造商，1955年成立，总部位于伊利诺伊州当纳斯格罗夫。2021年其业务分为五大板块：工程产品、清洁能源与加注、成像与识别、泵与工艺解决方案、气候与可持续技术，是标普500成分股，在纽约证券交易所上市。
LNTH vs RBC — 直观对比
营收规模更大
RBC
是对方的1.1倍
$406.8M
营收增速更快
RBC
高出13.0%
4.0%
净利率更高
RBC
高出1.3%
13.3%
自由现金流更多
RBC
多$17.7M
$81.4M
两年增速更快
RBC
近两年复合增速
4.9%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $406.8M | $461.6M |
| 净利润 | $54.1M | $67.4M |
| 毛利率 | 59.2% | 44.3% |
| 营业利润率 | 19.0% | 22.3% |
| 净利率 | 13.3% | 14.6% |
| 营收同比 | 4.0% | 17.0% |
| 净利润同比 | 558.8% | 16.4% |
| 每股收益（稀释后） | $0.86 | $2.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LNTHRBC
| Q4 25 | $406.8M | $461.6M | ||
| Q3 25 | $384.0M | $455.3M | ||
| Q2 25 | $378.0M | $436.0M | ||
| Q1 25 | $372.8M | $437.7M | ||
| Q4 24 | $391.1M | $394.4M | ||
| Q3 24 | $378.7M | $397.9M | ||
| Q2 24 | $394.1M | $406.3M | ||
| Q1 24 | $370.0M | $413.7M |
净利润LNTHRBC
| Q4 25 | $54.1M | $67.4M | ||
| Q3 25 | $27.8M | $60.0M | ||
| Q2 25 | $78.8M | $68.5M | ||
| Q1 25 | $72.9M | $72.7M | ||
| Q4 24 | $-11.8M | $57.9M | ||
| Q3 24 | $131.1M | $54.2M | ||
| Q2 24 | $62.1M | $61.4M | ||
| Q1 24 | $131.1M | — |
毛利率LNTHRBC
| Q4 25 | 59.2% | 44.3% | ||
| Q3 25 | 57.9% | 44.1% | ||
| Q2 25 | 63.8% | 44.8% | ||
| Q1 25 | 63.8% | 44.2% | ||
| Q4 24 | 63.5% | 44.3% | ||
| Q3 24 | 63.9% | 43.7% | ||
| Q2 24 | 64.9% | 45.3% | ||
| Q1 24 | 65.4% | 43.1% |
营业利润率LNTHRBC
| Q4 25 | 19.0% | 22.3% | ||
| Q3 25 | 11.4% | 21.5% | ||
| Q2 25 | 23.3% | 23.2% | ||
| Q1 25 | 27.4% | 23.0% | ||
| Q4 24 | 29.1% | 21.7% | ||
| Q3 24 | 35.3% | 21.6% | ||
| Q2 24 | 26.1% | 24.0% | ||
| Q1 24 | 28.8% | 22.8% |
净利率LNTHRBC
| Q4 25 | 13.3% | 14.6% | ||
| Q3 25 | 7.2% | 13.2% | ||
| Q2 25 | 20.8% | 15.7% | ||
| Q1 25 | 19.6% | 16.6% | ||
| Q4 24 | -3.0% | 14.7% | ||
| Q3 24 | 34.6% | 13.6% | ||
| Q2 24 | 15.8% | 15.1% | ||
| Q1 24 | 35.4% | — |
每股收益（稀释后）LNTHRBC
| Q4 25 | $0.86 | $2.13 | ||
| Q3 25 | $0.41 | $1.90 | ||
| Q2 25 | $1.12 | $2.17 | ||
| Q1 25 | $1.02 | $2.33 | ||
| Q4 24 | $-0.18 | $1.82 | ||
| Q3 24 | $1.79 | $1.65 | ||
| Q2 24 | $0.88 | $1.90 | ||
| Q1 24 | $1.87 | $1.92 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $359.1M | $107.6M |
| 总债务越低越好 | $568.7M | $990.2M |
| 股东权益账面价值 | $1.1B | $3.3B |
| 总资产 | $2.2B | $5.1B |
| 负债/权益比越低杠杆越低 | 0.52× | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资LNTHRBC
| Q4 25 | $359.1M | $107.6M | ||
| Q3 25 | $382.0M | $91.2M | ||
| Q2 25 | $695.6M | $132.9M | ||
| Q1 25 | $938.5M | $36.8M | ||
| Q4 24 | $912.8M | — | ||
| Q3 24 | $866.4M | — | ||
| Q2 24 | $757.0M | $76.8M | ||
| Q1 24 | $718.3M | $63.5M |
总债务LNTHRBC
| Q4 25 | $568.7M | $990.2M | ||
| Q3 25 | $567.9M | $1.1B | ||
| Q2 25 | $566.8M | $915.6M | ||
| Q1 25 | $566.1M | $920.1M | ||
| Q4 24 | $565.3M | — | ||
| Q3 24 | $613.0K | — | ||
| Q2 24 | $563.2M | — | ||
| Q1 24 | $562.5M | $1.2B |
股东权益LNTHRBC
| Q4 25 | $1.1B | $3.3B | ||
| Q3 25 | $1.1B | $3.2B | ||
| Q2 25 | $1.2B | $3.1B | ||
| Q1 25 | $1.2B | $3.0B | ||
| Q4 24 | $1.1B | $2.9B | ||
| Q3 24 | $1.2B | $2.9B | ||
| Q2 24 | $1.0B | $2.8B | ||
| Q1 24 | $945.5M | $2.8B |
总资产LNTHRBC
| Q4 25 | $2.2B | $5.1B | ||
| Q3 25 | $2.3B | $5.1B | ||
| Q2 25 | $2.1B | $4.8B | ||
| Q1 25 | $2.1B | $4.7B | ||
| Q4 24 | $2.0B | $4.7B | ||
| Q3 24 | $2.0B | $4.7B | ||
| Q2 24 | $1.9B | $4.7B | ||
| Q1 24 | $1.8B | $4.7B |
负债/权益比LNTHRBC
| Q4 25 | 0.52× | 0.30× | ||
| Q3 25 | 0.51× | 0.34× | ||
| Q2 25 | 0.49× | 0.29× | ||
| Q1 25 | 0.49× | 0.30× | ||
| Q4 24 | 0.52× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.55× | — | ||
| Q1 24 | 0.59× | 0.43× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $90.2M | $122.1M |
| 自由现金流经营现金流 - 资本支出 | $81.4M | $99.1M |
| 自由现金流率自由现金流/营收 | 20.0% | 21.5% |
| 资本支出强度资本支出/营收 | 2.2% | 5.0% |
| 现金转化率经营现金流/净利润 | 1.67× | 1.81× |
| 过去12个月自由现金流最近4个季度 | $354.1M | — |
8季度趋势，按日历期对齐
经营现金流LNTHRBC
| Q4 25 | $90.2M | $122.1M | ||
| Q3 25 | $105.3M | $88.4M | ||
| Q2 25 | $87.1M | $120.0M | ||
| Q1 25 | $107.6M | — | ||
| Q4 24 | $157.7M | $84.0M | ||
| Q3 24 | $175.1M | — | ||
| Q2 24 | $84.7M | $97.4M | ||
| Q1 24 | $127.2M | — |
自由现金流LNTHRBC
| Q4 25 | $81.4M | $99.1M | ||
| Q3 25 | $94.7M | $71.7M | ||
| Q2 25 | $79.1M | $104.3M | ||
| Q1 25 | $98.8M | — | ||
| Q4 24 | $141.4M | $73.6M | ||
| Q3 24 | $159.3M | — | ||
| Q2 24 | $73.5M | $88.4M | ||
| Q1 24 | $119.0M | — |
自由现金流率LNTHRBC
| Q4 25 | 20.0% | 21.5% | ||
| Q3 25 | 24.7% | 15.7% | ||
| Q2 25 | 20.9% | 23.9% | ||
| Q1 25 | 26.5% | — | ||
| Q4 24 | 36.1% | 18.7% | ||
| Q3 24 | 42.0% | — | ||
| Q2 24 | 18.7% | 21.8% | ||
| Q1 24 | 32.2% | — |
资本支出强度LNTHRBC
| Q4 25 | 2.2% | 5.0% | ||
| Q3 25 | 2.8% | 3.7% | ||
| Q2 25 | 2.1% | 3.6% | ||
| Q1 25 | 2.3% | 3.2% | ||
| Q4 24 | 4.2% | 2.6% | ||
| Q3 24 | 4.2% | 4.1% | ||
| Q2 24 | 2.8% | 2.2% | ||
| Q1 24 | 2.2% | — |
现金转化率LNTHRBC
| Q4 25 | 1.67× | 1.81× | ||
| Q3 25 | 3.79× | 1.47× | ||
| Q2 25 | 1.11× | 1.75× | ||
| Q1 25 | 1.47× | — | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | 1.36× | 1.59× | ||
| Q1 24 | 0.97× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LNTH
| Radiopharmaceutical Oncology | $240.2M | 59% |
| Definity | $85.3M | 21% |
| Strategic Partnerships And Other | $23.3M | 6% |
| Techne Lite | $21.0M | 5% |
| Licenseand Royalty Revenues | $17.4M | 4% |
| Other | $13.6M | 3% |
| Other Precision Diagnostics | $5.9M | 1% |
RBC
| Domestic | $413.3M | 90% |
| Foreign | $48.3M | 10% |
